Erlotinib or Gefitinib for the Treatment of Relapsed Platinum Pretreated NSCLC and Ovarian Cancer: a Systematic Review
نویسندگان
چکیده
Murphy, Mark and Stordal, Britta K. (2011) Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review. Drug Resistance Updates, 14 (3). pp. 177-90. ISSN 1368-7646 http://dx.doi.org/10.1016/j.drup.2011.02.004 Final accepted version (with author's formatting) Available from Middlesex University’s Research Repository at http://eprints.mdx.ac.uk/14444/
منابع مشابه
Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
BACKGROUND Platinum-based chemotherapy is the standard of care for ovarian cancer and non-small cell lung cancer (NSCLC). However, resistance to platinum agents invariably develops. Targeted therapies, such as tyrosine kinase inhibitors (TKIs), have great potential here as they exert their anti-tumour effect via alternative mechanisms to platinum-based drugs and as such may remain unaffected by...
متن کاملSystemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
PURPOSE To provide evidence-based recommendations to update the American Society of Clinical Oncology guideline on systemic therapy for stage IV non-small-cell lung cancer (NSCLC). METHODS An Update Committee of the American Society of Clinical Oncology NSCLC Expert Panel based recommendations on a systematic review of randomized controlled trials from January 2007 to February 2014. RESULTS...
متن کاملSystemic treatment of non-small cell lung cancer brain metastases
In the systemic treatment of brain metastases from non-small cell lung cancer (BMF-NSCLC) chemo- and targeted therapy are used. Response rates after platinum-based chemotherapy, range from 23% to 45%. Development of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): gefitinib or erlotinib, was an improvement in treatment of advanced NSCLC patients. EGFR mutations are prese...
متن کاملEGF Receptor Mutations in Primary Tumors and Lymph Nodes in NSCLC: a Review and Meta-analysis
Lung cancer is the leading cause of cancer-related mortality throughout the world and is expected to remain a major health problem for the foreseeable future (Jemal et al., 2009). Non-small cell lung cancer (NSCLC) accounts for 75-80% of all lung cancer cases (Hansen, 2002). Patients with early stage NSCLC have long-term survival with surgical resection. However, most NSCLC patients were at an ...
متن کاملNew insights in drug development for the non-small cell lung cancer therapy.
Non-small cell lung cancer (NSCLC) remains a major problem worldwide. Since most patients with NSCLC have advanced disease at diagnosis, to date, chemotherapy, with third-generation platinum-based doublets, represents the standard of care. However, a plateau has been reached with the use of cytotoxic chemotherapy in advanced NSCLC. Advances in the knowledge of tumour biology and mechanisms of o...
متن کامل